Anavex Life Sciences
AVXL Real Time Price USDRecent trades of AVXL by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by AVXL's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Treatment of cardiac dysfunction Nov. 12, 2024
-
Patent Title: Analgesic therapeutic and method, 1-(3-4(((1r,3s,5s)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof Feb. 13, 2024
-
Patent Title: Neurodevelopmental disorder therapy Dec. 12, 2023
-
Patent Title: A2-73 as a therapeutic for insomnia, anxiety, and agitation Nov. 14, 2023
-
Patent Title: A19-144, a2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy Jul. 04, 2023
-
Patent Title: Crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions May. 30, 2023
-
Patent Title: Sigma-1 receptor agonist systolic blood pressure therapy Apr. 11, 2023
-
Patent Title: A2-73 crystalline polymorph compositions of matter and methods of use thereof Nov. 15, 2022
-
Patent Title: Neurodevelopmental disorder therapy Sep. 20, 2022
-
Patent Title: A2-73 as a therapeutic for insomnia, anxiety, and agitation May. 24, 2022
-
Patent Title: Anavex2-73 for the treatment of alzheimer's disease Aug. 31, 2021
-
Patent Title: Treatment of cardiac dysfunction Jul. 27, 2021
-
Patent Title: Crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions Apr. 06, 2021
-
Patent Title: Analgesic therapeutic and method, 1-(3-4(((1 r,3s,5s)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof Mar. 02, 2021
-
Patent Title: Neurodevelopmental disorder therapy Jan. 12, 2021
-
Patent Title: A19-144, a2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy Oct. 27, 2020
-
Patent Title: Neurodevelopmental disorder therapy Dec. 17, 2019
-
Patent Title: A19-144, a2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy Oct. 15, 2019
-
Patent Title: Crystalline form of anavex2-73 for the treatment of alzheimer's disease Oct. 01, 2019
-
Patent Title: Crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions Sep. 17, 2019
-
Patent Title: Analgesic therapeutic and method, 1-(3-4(((1r,3s,5s)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof Feb. 05, 2019
-
Patent Title: Anavex2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection Sep. 05, 2017
-
Patent Title: Sigma receptors ligands with anti-apoptotic and/or pro-apoptotic properties, over cellular mechanisms, exhibiting prototypical cytoprotective and also anti-cancer activity Nov. 10, 2015
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of AVXL in WallStreetBets Daily Discussion
Recent insights relating to AVXL
Recent picks made for AVXL stock on CNBC
ETFs with the largest estimated holdings in AVXL
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view AVXL Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.